Semaglutide (CAS 910463-68-2) – Research Grade is a high-purity chemical compound.

Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.

Research Context

Semaglutide, a glucagon-like peptide-1 (GLP-1) analog, has garnered significant attention in the field of diabetes and obesity research. As an innovative therapeutic agent, it mimics the action of native GLP-1, promoting insulin secretion in response to elevated blood glucose levels, while simultaneously inhibiting glucagon release. This dual mechanism contributes to glycemic control and weight loss, making semaglutide a valuable option for managing type 2 diabetes and obesity.

Research Applications

In clinical trials, semaglutide has shown remarkable efficacy in lowering HbA1c levels and achieving weight reduction. It is typically administered via subcutaneous injection and is available in both weekly and daily formulations, allowing for flexible patient adherence. Beyond its primary use in diabetes management, emerging studies are exploring its potential in cardiovascular health, neurodegenerative diseases, and weight management in non-diabetic populations. Researchers are also investigating its role in metabolic syndrome and fatty liver disease, highlighting its broad applicability in endocrine and metabolic disorders.

Solubility and Storage Advice

Semaglutide is soluble in water, which facilitates its formulation for injection. For optimal stability, it should be stored in a refrigerator at temperatures between 2°C and 8°C (36°F and 46°F). It is essential to protect semaglutide from light and to avoid freezing to ensure the integrity of the compound. Once in use, it can be kept at room temperature for limited durations, as specified in the product guidelines.

Future Research Directions

The future of semaglutide research is promising, with ongoing investigations focusing on long-term safety and efficacy, combination therapies with other antidiabetic agents, and its potential applications in treating other metabolic disorders. Studies are also examining the effects of semaglutide on satiety and appetite regulation, which could provide deeper insights into its mechanisms and broaden its therapeutic uses. As the understanding of GLP-1 receptor agonists evolves, semaglutide may pave the way for novel interventions that improve health outcomes in diverse patient populations.